The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APVO | -99.21% | -100% | -93.72% | -100% |
| S&P | +13.19% | +87.83% | +13.42% | +210% |
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.05M | 0.0% |
| Market Cap | $4.77M | 55.5% |
| Market Cap / Employee | $0.11M | 0.0% |
| Employees | 42 | 5.0% |
| Net Income | -$9.03M | -77.0% |
| EBITDA | -$7.56M | -47.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $21.06M | 171.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.99M | -17.4% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -132.66% | -19.0% |
| Return On Invested Capital | -109.88% | 5.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.69M | -28.1% |
| Operating Free Cash Flow | -$6.69M | -28.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.32 | -1.15 | -0.15 | 0.72 | 3.32% |
| Price to Tangible Book Value | 8.99 | 7.12 | -0.15 | 0.72 | -99.41% |
| Enterprise Value to EBITDA | -0.35 | -0.62 | 0.48 | 1.48 | 640.23% |
| Return on Equity | -284.3% | -1023.9% | -437.3% | -256.3% | 2.13% |
| Total Debt | $4.63M | $4.42M | $4.21M | $3.99M | -17.39% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
